{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:59:13Z","timestamp":1794581953645,"version":"4.9.1"},"reference-count":165,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>It is known that both psoriasis (PSO) limited to the skin and psoriatic arthritis (PSA) increase the risk of cardiovascular complications and atherosclerosis progression by inducing systemic inflammatory response. In recent decades, the introduction of biological medications directed initially against TNF-\u03b1 and, later, different targets in the inflammatory cascade brought a significant breakthrough in the efficacy of PSO\/PSA treatment. In this review, we present and discuss the most recent findings related to the interplay between the genetics and immunology mechanisms involved in PSO and PSA, atherosclerosis and the development of cardiac dysfunction, as well as the current PSO\/PSA treatment in view of cardiovascular safety and prognosis.<\/jats:p>","DOI":"10.3390\/ijms221910402","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:39:20Z","timestamp":1632739160000},"page":"10402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Psoriasis and Atherosclerosis\u2014Skin, Joints, and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-5389","authenticated-orcid":false,"given":"Karina","family":"Wierzbowska-Drabik","sequence":"first","affiliation":[{"name":"Department of Cardiology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Lesiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Skibi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-629X","authenticated-orcid":false,"given":"Micha\u0142","family":"Nied\u017awied\u017a","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw D.","family":"Kasprzak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Narbutt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Koppikar, S., Colaco, K., Harvey, P., Akhtari, S., Chandran, V., Gladman, D.D., Cook, R., and Eder, L. (2021). Incidence of and Risk Factors for Heart Failure in Patients with Psoriatic Disease\u2014A Cohort Study. Arthritis Care Res.","DOI":"10.1002\/acr.24578"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ejhf.1902","article-title":"Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure with a Preserved Ejection Fraction: A Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease","volume":"22","author":"Packer","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and Cardiovascular Risk: A Comprehensive Review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A Systematic Review of Worldwide Epidemiology of Psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM197304262881715","article-title":"Occlusive Vascular Disease in Psoriatic Patients","volume":"288","author":"McDonald","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of Risk Factors for Myocardial Infarction and Other Vascular Diseases in Patients with Psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/jid.2009.321","article-title":"Psoriasis May Not Be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort","volume":"130","author":"Wakkee","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis Is Associated with Clinically Significant Cardiovascular Risk: A Danish Nationwide Cohort Study: Psoriasis and Cardiovascular Risk","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bjd.12002","article-title":"Association of Psoriasis with Stroke and Myocardial Infarction: Meta-Analysis of Cohort Studies: Psoriasis, Stroke and Myocardial Infarction","volume":"167","author":"Xu","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: A Possible Risk Factor for Development of Coronary Artery Calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000182256","article-title":"Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness","volume":"218","author":"Gisondi","year":"2009","journal-title":"Dermatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","article-title":"Impact of Effective Tumor Necrosis Factor-Alfa Inhibitor Treatment on Arterial Intima-Media Thickness in Psoriasis: Results of a Pilot Study","volume":"69","author":"Szakonyi","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2018.07.007","article-title":"Femoral Artery Ultrasound for Improving the Detection of Atherosclerosis in Psoriasis","volume":"80","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e3576","DOI":"10.1097\/MD.0000000000003576","article-title":"Association between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis","volume":"95","author":"Fang","year":"2016","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Villasante Fricke, A.C., and Iacobellis, G. (2019). Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235989"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00403-015-1586-7","article-title":"Influence of Psoriasis on Circulatory System Function Assessed in Echocardiography","volume":"307","author":"Milaniuk","year":"2015","journal-title":"Arch. Derm. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00508-015-0817-4","article-title":"Assessment of Left Atrial Volume and Function in Patients with Psoriasis by Using Real Time Three-Dimensional Echocardiography","volume":"127","author":"Atas","year":"2015","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13756","DOI":"10.1111\/ijcp.13756","article-title":"Cardiomyopathy and Echocardiographic Abnormalities in Indian Patients with Psoriasis: Results of a Pilot Study","volume":"75","author":"Rana","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink","volume":"135","author":"Parisi","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-008-8094-x","article-title":"Atherosclerosis in Autoimmune Rheumatic Diseases-Mechanisms and Clinical Findings","volume":"37","author":"Zinger","year":"2009","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.autrev.2010.07.016","article-title":"From Endothelial Dysfunction to Atherosclerosis","volume":"9","author":"Sitia","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000153339.27064.14","article-title":"Endothelial Function: Cardiac Events","volume":"111","author":"Lerman","year":"2005","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with Severe Psoriasis Are at Increased Risk of Cardiovascular Mortality: Cohort Study Using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12016-012-8308-0","article-title":"Inflammation, Atherosclerosis, and Psoriasis","volume":"44","author":"Siegel","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-Specific Mortality in Patients with Severe Psoriasis: A Population-Based Cohort Study in the U.K: Cause-Specific Mortality in Patients with Severe Psoriasis","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Patients with Psoriatic Arthritis Compared to Patients without Psoriatic Arthritis","volume":"21","author":"Li","year":"2015","journal-title":"J. Clin. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/annrheumdis-2016-210390","article-title":"Increased Prevalence of Coronary Plaque in Patients with Psoriatic Arthritis without Prior Diagnosis of Coronary Artery Disease","volume":"76","author":"Shen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1468-3083.2012.04706.x","article-title":"Arthritis as an Important Determinant for Psoriatic Patients to Develop Severe Vascular Events in Taiwan: A Nation-Wide Study: Psoriasis with or without Joint Involvement","volume":"27","author":"Chin","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/JID.2015.385","article-title":"Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile","volume":"136","author":"Tom","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.38227","article-title":"Hypercholesterolemia and Risk of Incident Psoriasis and Psoriatic Arthritis in US Women: Hypercholesterolemia and Risk of Incident Psoriasis and PsA","volume":"66","author":"Wu","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom: A Population-Based Study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1194\/jlr.M027367","article-title":"Psoriasis Alters HDL Composition and Cholesterol Efflux Capacity","volume":"53","author":"Holzer","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.5114\/ada.2019.91420","article-title":"Evaluation of Serum Lipid, Lipoprotein, and Apolipoprotein Levels in Psoriatic Patients: A Systematic Review and Meta-Analysis of Case-Control Studies","volume":"36","author":"Ramezani","year":"2019","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-016-0271-y","article-title":"Epicardial Fat Tissue in Patients with Psoriasis: A Systematic Review and Meta-Analysis","volume":"15","author":"Wang","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000472149","article-title":"Glycemic Control in the Treatment of Psoriasis","volume":"233","author":"Ip","year":"2017","journal-title":"Dermatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00403-017-1748-x","article-title":"Serum Fatty Acid Profile in Psoriasis and Its Comorbidity","volume":"309","author":"Baran","year":"2017","journal-title":"Arch. Derm. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses\u2019 Health Study II: Nurses\u2019 Health Study II","volume":"167","author":"Setty","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clindermatol.2014.12.006","article-title":"Obesity and the Metabolic Syndrome in Pediatric Psoriasis","volume":"33","author":"Shah","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.orcp.2017.04.008","article-title":"Morbid Obesity and Psoriasis: Disease Remission after Laparoscopic Sleeve Gastrectomy","volume":"11","author":"Babino","year":"2017","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The Effect of Weight Reduction on Treatment Outcomes in Obese Patients with Psoriasis on Biologic Therapy: A Randomized Controlled Prospective Trial","volume":"14","author":"Nour","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased Expression of Interleukin 17 in Inflammatory Bowel Disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jmg.2007.053595","article-title":"Psoriasis Is Associated with Pleiotropic Susceptibility Loci Identified in Type II Diabetes and Crohn Disease","volume":"45","author":"Wolf","year":"2008","journal-title":"J. Med. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"983902","DOI":"10.1155\/2013\/983902","article-title":"Correlations between Psoriasis and Inflammatory Bowel Diseases","volume":"2013","author":"Skroza","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the Microbiota in Immunity and Inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients with Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease: Gut Microbiota in PsA","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Olejniczak-Staruch, I., Ci\u0105\u017cy\u0144ska, M., Sobolewska-Sztychny, D., Narbutt, J., Skibi\u0144ska, M., and Lesiak, A. (2021). Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083998"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of Psoriasis with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","article-title":"Hypertension, Antihypertensive Medication Use, and Risk of Psoriasis","volume":"150","author":"Wu","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The Role of the Interleukin-23\/Th17 Pathway in Cardiometabolic Comorbidity Associated with Psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1203475415616073","article-title":"Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis with Qualitative Analysis of Effect of Smoking on Psoriasis Severity: A Systematic Literature Review and Meta-Analysis with Qualitative Analysis of Effect of Smoking on Psoriasis Severity","volume":"20","author":"Richer","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0625.2010.01224.x","article-title":"Tobacco Smoke Is Related to Th17 Generation with Clinical Implications for Psoriasis Patients: Letter to the Editor","volume":"20","author":"Torii","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients with Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The Risk of Stroke in Patients with Psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A Population-Based Cohort Study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1160\/TH17-01-0039","article-title":"Increased Risks of Venous Thromboembolism in Patients with Psoriasis. A Nationwide Cohort Study: A Nationwide Cohort Study","volume":"117","author":"Chung","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2012.04646.x","article-title":"Psoriasis Is Associated with a Greater Risk of Incident Venous Thromboembolism: The Iowa Women\u2019s Health Study: Letters to the Editor","volume":"10","author":"Lutsey","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ahlehoff, O., Gislason, G.H., Lindhardsen, J., Charlot, M.G., J\u00f8rgensen, C.H., Olesen, J.B., Bretler, D.-M., Skov, L., Torp-Pedersen, C., and Hansen, P.R. (2011). Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018125"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Awareness and Attention to Comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/07853890.2021.1942974","article-title":"Venous Thrombotic Events in Psoriasis Patients: A Systematic Review with Meta-Analysis","volume":"53","author":"Hillary","year":"2021","journal-title":"Ann. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ejhf.113","article-title":"Psoriasis and Risk of Heart Failure: A Nationwide Cohort Study: Psoriasis and Risk of Heart Failure: A Nationwide Cohort Study","volume":"16","author":"Khalid","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000121605","article-title":"Psoriasis and Dilated Cardiomyopathy: Coincidence or Associated Diseases?","volume":"111","author":"Shuvy","year":"2008","journal-title":"Cardiology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis: A Systematic Review and Meta-Analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy Risk and Recurrence with Psoriasis and Its Treatments: A Concise Update","volume":"19","author":"Geller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin Cancer in Patients with Psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/bjd.16245","article-title":"Psoriasis and Risk of Malignant Lymphoma: A Population-Based Cohort Study","volume":"178","author":"Kamstrup","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The Risk of Squamous Cell and Basal Cell Cancer Associated with Psoralen and Ultraviolet A Therapy: A 30-Year Prospective Study","volume":"66","author":"Stern","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/jdv.14365","article-title":"Psoriasis in Patients with Mycosis Fungoides: A Clinicopathological Study of 25 Patients","volume":"31","author":"Nikolaou","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of Cancer in Psoriasis: A Systematic Review and Meta-Analysis of Epidemiological Studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A Comparison of the Malignancy Incidence among Patients with Psoriatic Arthritis and Patients with Rheumatoid Arthritis in a Large US Cohort: Malignancy in Psoriatic Arthritis and Rheumatoid Arthritis","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.14698","article-title":"Cancer Risk in 892 089 Patients with Psoriasis in Korea: A Nationwide Population-Based Cohort Study","volume":"46","author":"Lee","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chiu, H.-Y., Hsieh, C.-F., Chiang, Y.-T., Tsai, Y.-W., Huang, W.-F., Li, C.-Y., Wang, T.-S., and Tsai, T.-F. (2016). Concomitant Sleep Disorders Significantly Increase the Risk of Cardiovascular Disease in Patients with Psoriasis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146462"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1684\/ejd.2013.1965","article-title":"Anxiety Contributes to the Development of Cerebrovascular Disease in Taiwanese Patients with Psoriasis: A Population-Based Study","volume":"23","author":"Lan","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2340\/00015555-2218","article-title":"Impact of Depression on Risk of Myocardial Infarction, Stroke and Cardiovascular Death in Patients with Psoriasis: A Danish Nationwide Study","volume":"96","author":"Egeberg","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of Life in Psoriasis Patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_83","first-page":"198","article-title":"Do Psoriasis Patients Engage in Vigorous Physical Activity?","volume":"101","author":"Amin","year":"2018","journal-title":"Cutis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archdermatol.2012.943","article-title":"The Association between Physical Activity and the Risk of Incident Psoriasis","volume":"148","author":"Frankel","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14712598.2018.1479738","article-title":"Limitations of Current Monoclonal Antibodies for Plaque-Type Psoriasis and an Outlook for the Future","volume":"18","author":"Raimondo","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u201cPsoriatic March\u201d: A Concept of How Severe Psoriasis May Drive Cardiovascular Comorbidity: The \u2018Psoriatic March\u2018","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1600-0625.2011.01308.x","article-title":"A Tale of Two Plaques: Convergent Mechanisms of T-Cell-Mediated Inflammation in Psoriasis and Atherosclerosis: T-Cell Immunology in Psoriasis and Atherosclerosis","volume":"20","author":"Armstrong","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/eurheartj\/ehr425","article-title":"Psoriasis and Atherosclerosis: Two Plaques, One Syndrome?","volume":"33","author":"Flammer","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.det.2014.09.004","article-title":"Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities","volume":"33","author":"Ryan","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7150\/ijms.7.284","article-title":"Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease","volume":"7","author":"Ghazizadeh","year":"2010","journal-title":"Int. J. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000314626","article-title":"Emerging Role of IL-17 in Atherosclerosis","volume":"2","author":"Chen","year":"2010","journal-title":"J. Innate Immun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1479-5876-11-194","article-title":"Modulation of Cardiometabolic Pathways in Skin and Serum from Patients with Psoriasis","volume":"11","author":"Mehta","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.mca.0000236288.94553.b4","article-title":"Role of Interleukin-17 and Interleukin-17-Induced Cytokines Interleukin-6 and Interleukin-8 in Unstable Coronary Artery Disease","volume":"17","author":"Hashmi","year":"2006","journal-title":"Coron. Artery Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ijd.13420","article-title":"Interleukin-17 as a factor linking the pathogenesis of psoriasiswith metabolic disorders","volume":"56","author":"Placek","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fimmu.2018.00139","article-title":"Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors","volume":"9","author":"Cosentino","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bjd.15149","article-title":"Increased Global Arterial and Subcutaneous Adipose Tissue Inflammation in Patients with Moderate-to-Severe Psoriasis","volume":"176","author":"Hjuler","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1346-8138.12859","article-title":"Subclinical Systemic and Vascular Inflammation Detected by (18) F-Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Patients with Mild Psoriasis","volume":"42","author":"Youn","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/jid.2012.112","article-title":"Chronic Skin-Specific Inflammation Promotes Vascular Inflammation and Thrombosis","volume":"132","author":"Wang","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_100","first-page":"1394","article-title":"Expression of NLRP3 inflammasome in BALB\/c mice with imiquimod-induced psoriasis-like inflammation and therapeutic effect of mustard seed (Sinapis Alba Linn)","volume":"33","author":"Hu","year":"2013","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/jid.2013.57","article-title":"A Toll-like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis","volume":"133","author":"Jiang","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ci\u0105\u017cy\u0144ska, M., Olejniczak-Staruch, I., Sobolewska-Sztychny, D., Narbutt, J., Skibi\u0144ska, M., and Lesiak, A. (2021). The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis: Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115898"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/jid.2012.366","article-title":"Association of Cardiovascular and Metabolic Disease Genes with Psoriasis","volume":"133","author":"Lu","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2005.06950.x","article-title":"Apolipoprotein E Gene Polymorphisms Are Associated with Psoriasis but Do Not Determine Disease Response to Acitretin: ApoE Gene Polymorphisms, Psoriasis and Acitretin","volume":"154","author":"Campalani","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2014.05.010","article-title":"Genetic Variation at IL12B, IL23R and IL23A Is Associated with Psoriasis Severity, Psoriatic Arthritis and Type 2 Diabetes Mellitus","volume":"75","author":"Queiro","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00011-017-1065-z","article-title":"\u201cInflammatory Skin March\u201d in Atopic Dermatitis and Psoriasis","volume":"66","author":"Furue","year":"2017","journal-title":"Inflamm. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in Atherosclerosis: From Pathophysiology to Practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hu, S., and Lan, C.-C.E. (2017). Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102211"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/08820139.2015.1095208","article-title":"Vitamin A Decreases Cytotoxicity of Oxidized Low-Density Lipoprotein in Patients with Atherosclerosis","volume":"45","author":"Mahmoudi","year":"2016","journal-title":"Immunol. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00403-010-1108-6","article-title":"Systemic Therapy of Plaque-Type Psoriasis Ameliorates Endothelial Cell Function: Results of a Prospective Longitudinal Pilot Trial","volume":"303","author":"Boehncke","year":"2011","journal-title":"Arch. Derm. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_113","first-page":"318","article-title":"Advancements in the Treatment of Psoriasis: Role of Biologic Agents","volume":"10","author":"Rich","year":"2004","journal-title":"J. Manag. Care Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/jdv.12814","article-title":"Anti-TNF-\u03b1 Therapy Improves Insulin Sensitivity in Non-Diabetic Patients with Psoriasis: A 6-Month Prospective Study","volume":"29","author":"Pina","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5114\/ada.2017.67077","article-title":"Long-Term Treatment of Chronic Plaque Psoriasis with Biological Drugs Can Control Platelet Activation: Targeting the Bridge between Inflammation and Atherothrombosis","volume":"34","author":"Kwiek","year":"2017","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jdv.13005","article-title":"Anti-TNF-\u03b1 Therapy Reduces Retinol-Binding Protein 4 Serum Levels in Non-Diabetic Patients with Psoriasis: A 6-Month Prospective Study","volume":"30","author":"Pina","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1346-8138.13398","article-title":"Anti-Tumor Necrosis Factor-Alpha Therapy Improves Endothelial Function and Arterial Stiffness in Patients with Moderate to Severe Psoriasis: A 6-Month Prospective Study","volume":"43","author":"Pina","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e006283","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared with Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A Phase III, Randomized, Controlled Trial of the Fully Human IL-12\/23 MAb Briakinumab in Moderate-to-Severe Psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A Human Interleukin-12\/23 Monoclonal Antibody for the Treatment of Psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis--Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","article-title":"Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCIMAGING.112.975730","article-title":"Effects of the Tumor Necrosis Factor-\u03b1 Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients with Psoriasis: Results of a Randomized Controlled Trial: Results of a Randomized Controlled Trial","volume":"6","author":"Bissonnette","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","article-title":"Association between Changes in Coronary Artery Disease Progression and Treatment with Biologic Agents for Severe Psoriasis","volume":"152","author":"Hjuler","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jdv.13152","article-title":"Myocardial Function and Effects of Biologic Therapy in Patients with Severe Psoriasis: A Prospective Echocardiographic Study","volume":"30","author":"Ahlehoff","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/jdv.13649","article-title":"Subclinical Cardiovascular Disease and It\u2019s Improvement after Long-Term TNF-\u03b1 Inhibitor Therapy in Severe Psoriatic Patients","volume":"30","author":"Varga","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL): Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 Stimulates Epidermal Hyperplasia via TNF and IL-20R2-Dependent Mechanisms with Implications for Psoriasis Pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/STROKEAHA.114.006516","article-title":"Interleukin 23 Levels Are Increased in Carotid Atherosclerosis: Possible Role for the Interleukin 23\/Interleukin 17 Axis","volume":"46","author":"Abbas","year":"2015","journal-title":"Stroke"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12016-012-8306-2","article-title":"Cytokine-based therapy in psoriasis","volume":"44","author":"Mitra","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular Safety of Ustekinumab in Patients with Moderate to Severe Psoriasis: Results of Integrated Analyses of Data from Phase II and III Clinical Studies: Cardiovascular Safety of Ustekinumab in Clinical Trials of Psoriasis","volume":"164","author":"Reich","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1346-8138.2010.00802.x","article-title":"Positive Treatment Effects of Ustekinumab in Psoriasis: Analysis of Lesional and Systemic Parameters: Ustekinumab Has Minimal Systemic Effects","volume":"37","author":"Reddy","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/jdv.14125","article-title":"Efficacy and Safety of Interleukin-17 Antagonists in Patients with Plaque Psoriasis: A Meta-Analysis from Phase 3 Randomized Controlled Trials","volume":"31","author":"Wu","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab Long-Term Safety Experience: A Pooled Analysis of 10 Phase II and III Clinical Studies in Patients with Moderate to Severe Plaque Psoriasis","volume":"75","author":"Griffiths","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and Long-Term Safety Outcomes with Ixekizumab from 7 Clinical Trials in Psoriasis: Etanercept Comparisons and Integrated Data","volume":"76","author":"Strober","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Amoruso, G.F., Nistic\u00f2, S.P., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab May Improve Renal Function in Psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A Prospective Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_143","unstructured":"European Medicines Agency (2021, September 19). Summary of Product Characteristics\u2014Bimzelx. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for Patients with Moderate to Severe Plaque Psoriasis: 60-Week Results from BE ABLE 2, a Randomized, Double-Blinded, Placebo-Controlled, Phase 2b Extension Study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of Biologic Therapies on Risk of Major Adverse Cardiovascular Events in Patients with Psoriasis: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s13205-020-2089-6","article-title":"Psoriasis and Cardiovascular Disorders: Association or Epiphenomenon? Meta-Analysis of Observational Studies","volume":"10","author":"Choudhary","year":"2020","journal-title":"3 Biotech"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1136\/annrheumdis-2013-203433","article-title":"The Framingham Risk Score Underestimates the Extent of Subclinical Atherosclerosis in Patients with Psoriatic Disease","volume":"73","author":"Eder","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1468-3083.2012.04618.x","article-title":"Psoriasis and Cardiovascular Risk. Assessment by Different Cardiovascular Risk Scores: Psoriasis and Cardiovascular Risk Scores","volume":"27","author":"Fonseca","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR Recommendations for Cardiovascular Disease Risk Management in Patients with Rheumatoid Arthritis and Other Forms of Inflammatory Joint Disorders: 2015\/2016 Update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_151","first-page":"426","article-title":"The Mechanism of Lithium and Beta-Blocking Agents in Inducing and Exacerbating Psoriasis","volume":"5","author":"Koo","year":"2006","journal-title":"J. Drugs Dermatol."},{"key":"ref_152","first-page":"202","article-title":"Cutaneous Effects of Antihypertensive Drugs. G","volume":"155","author":"Baccino","year":"2020","journal-title":"Ital. Dermatol. Venereol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12895-016-0049-y","article-title":"Randomized Placebo Control Study of Insulin Sensitizers (Metformin and Pioglitazone) in Psoriasis Patients with Metabolic Syndrome (Topical Treatment Cohort)","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of Psoriasis during Glucagon-like Peptide-1 Analogue Therapy in Type 2 Diabetes Is Associated with Decreasing Dermal \u0393\u03b4 T-Cell Number: A Prospective Case-Series Study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes May Reduce the Risk of Autoimmune Diseases: A Population-Based Cohort Study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results from Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_157","unstructured":"(2021, September 19). Lilly\u2019s Mirikizumab Superior to Cosentyx (Secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis. Available online: https:\/\/investor.lilly.com\/node\/43481\/pdf."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1111\/dth.14504","article-title":"Emerging Role of Anti-IL23 in the Treatment of Psoriasis: When Humanized Is Very Promising","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic Treatment of Psoriasis with JAK Inhibitors: A Review","volume":"10","author":"Hansen","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Results from Two Randomized, Placebo-Controlled, Phase III Trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_162","unstructured":"European Medicines Agency (2021, September 19). Summary of Product Characteristics\u2014Xeljanz. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of Tofacitinib on Lipid Levels and Lipid-Related Parameters in Patients with Moderate to Severe Psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e14721","DOI":"10.1111\/dth.14721","article-title":"Novel Anti-Inflammatory Therapies to Reduce Cardiovascular Burden of Psoriasis","volume":"34","author":"Piros","year":"2021","journal-title":"Dermatol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/19\/10402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:05:46Z","timestamp":1760166346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/19\/10402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":165,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["ijms221910402"],"URL":"https:\/\/doi.org\/10.3390\/ijms221910402","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]}}}